EUVIMEDEUVIMED entdecken
Crossref

Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma

Eleanor E Handel, Janet McKeown, Joe Wei, Roma A Kankaria, Hannah Burnette, Douglas B Johnson, Aleigha Lawless, Juliane Czapla, Ryan J Sullivan, Lea Jessica Albrecht, Lisa Zimmer, Joanna Mangana und 15 weitere

European Journal of Cancer · 2025

DOI: 10.1016/j.ejca.2024.115171 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Eleanor E Handel und 26 weiteren Autor:innen. Beteiligte Einrichtung: Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, NSW, Australia. Electronic address: eleanor.handel@health.nsw.gov.au. Hauptthemen laut MEDLINE: Melanoma, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 14 Literaturangaben. Gefördert von: National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaImmune Checkpoint InhibitorsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultAged, 80 and overDisease ProgressionSkin NeoplasmsTreatment OutcomeTime FactorsYoung AdultNeoplasm Recurrence, LocalFollow-Up Studies

Stichwörter der Autor:innen

Checkpoint inhibitorsImmunotherapyMelanomaSurvival

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, NSW, Australia. Electronic address: eleanor.handel@health.nsw.gov.au.
  • Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
  • Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, NSW, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
  • Vanderbilt-Ingram Cancer Centre, Nashville, TN, USA.
  • Massachusetts General Hospital, Boston, MA, USA.
  • Department of Dermatology, University Hospital Essen, Essen, Germany.

Förderung

  • National Health and Medical Research Council

Zitieren

APA

Handel, E. E., McKeown, J., Wei, J., Kankaria, R. A., Burnette, H., Johnson, D. B., Lawless, A., Czapla, J., Sullivan, R. J., Albrecht, L. J., Zimmer, L., Mangana, J., Dummer, R., Kessels, J. I., Neyns, B., Allayous, C., Lebbe, C., Boatwright, C., Mehnert, J. M., …, & Carlino, M. S. (2025). Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.115171

Vancouver

Handel EE, McKeown J, Wei J, Kankaria RA, Burnette H, Johnson DB, et al. Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2024.115171

BibTeX
@article{Handel2025,
  author = {Handel, Eleanor E and McKeown, Janet and Wei, Joe and Kankaria, Roma A and Burnette, Hannah and Johnson, Douglas B and Lawless, Aleigha and Czapla, Juliane and Sullivan, Ryan J and Albrecht, Lea Jessica and Zimmer, Lisa and Mangana, Joanna and Dummer, Reinhard and Kessels, Jolien I and Neyns, Bart and Allayous, Clara and Lebbe, Celeste and Boatwright, Christina and Mehnert, Janice M and Ottaviano, Margaret and Ascierto, Paolo A and Czarnecka, Anna M and Rutkowski, Piotr and Lo, Serigne N and Long, Georgina V and Menzies, Alexander M and Carlino, Matteo S},
  title = {Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma},
  journal = {European Journal of Cancer},
  year = {2025},
  doi = {10.1016/j.ejca.2024.115171}
}
Kostenlos starten →